Obianda, Anna Mae T.
HRN: 20-40-41 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/24/2022
METRONIDAZOLE 500MG (TAB)
05/24/2022
05/31/2022
ORAL
500mg
Q8
Thickly MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes